Engineered nanoparticles built around indocyanine green, a fluorescent dye already approved for clinical use, could sharpen how surgeons see and remove tumors during operations. A study in the journal Nanotheranostics describes a formulation called “ICG-Glow” that wraps the dye in a polymer–tannic acid shell, boosting its stability and its ability to home in on cancer cells in near-infrared light. The work adds to a growing body of preclinical research suggesting that packaging ICG inside nanoparticles can solve the dye’s well-known shortcomings and deliver brighter, longer-lasting tumor signals.
Why Free ICG Falls Short in Surgery
Indocyanine green has been used in medical imaging for decades. It fluoresces in the near-infrared window, a range of light that penetrates tissue more deeply than visible wavelengths, making it useful for spotting blood flow and organ boundaries during procedures. But the dye has serious limits when applied to cancer surgery. A peer-reviewed review in the International Journal of Nanomedicine catalogs the problems: signal-to-background challenges, rapid clearance, photodegradation, and poor tumor specificity. Free ICG does not preferentially accumulate in tumors; it washes through the bloodstream quickly and loses brightness under sustained light exposure. Surgeons relying on it can struggle to distinguish malignant margins from healthy tissue, raising the risk of leaving cancer behind or cutting away too much.
These constraints have driven a wave of nanoparticle-based strategies. The logic is straightforward: encapsulate ICG in a carrier that protects it from degradation, extends its circulation time, and steers it toward tumor cells through surface chemistry or size-dependent accumulation. The key question is which carrier design actually delivers on that promise in living systems, and how those designs compare across different tumor models and imaging platforms.
How ICG-Glow Nanoparticles Work
The ICG-Glow formulation takes a two-step approach. First, polyvinylpyrrolidone (PVP) and ICG self-assemble into a core particle. Then a coating of tannic acid is applied, creating a cloak that improves the particle’s colloidal stability and its interactions with biological tissue. The resulting probe is designed for near-infrared imaging with improved photostability, longer circulation and retention, and greater tumor-cell specificity compared to free ICG alone. Characterization data in the study report a particle size of roughly 125 nanometers, a dimension small enough to exploit the enhanced permeability and retention effect that allows nanoparticles to leak preferentially into tumor vasculature.
The tannic acid shell is not just structural. Polyphenol coatings like tannic acid can interact with proteins on cell surfaces and may show affinity for certain receptors overexpressed on cancer cells. That dual function (protecting the dye while also guiding it) is what separates ICG-Glow from simpler encapsulation strategies. The study, indexed under this DOI, lays out quantitative imaging data in mouse tumor models, though all experiments remain at the preclinical stage. The authors report enhanced tumor-to-background ratios and more persistent fluorescence signals, suggesting that the formulation could give surgeons a clearer map of malignant tissue during resection.
Earlier Nanoparticle Designs Set the Stage
ICG-Glow did not emerge in a vacuum. An earlier formulation called NanoICG used hyaluronic-acid-derived nanoparticles to physically entrap ICG and was tested in breast tumor xenografts with image-guided surgery systems. That work demonstrated improved tumor delivery and fluorescence enhancement relative to free dye, and it included biodistribution analysis showing where the particles ended up after injection. NanoICG leveraged the natural affinity of hyaluronic acid for CD44 receptors, which are frequently upregulated on certain cancer cells, to drive uptake into tumors.
A follow-up evaluation expanded the comparison to a panel of near-infrared fluorescence contrast agents, analyzing tumor contrast, cellular uptake, and depth detection in tissue-mimicking phantoms using the same MDA-MB-231 tumor model. These studies established that hyaluronic-acid carriers could meaningfully improve signal quality, particularly in the context of real-time surgical guidance. But they also exposed trade-offs. CD44 targeting is powerful where that receptor is abundant, yet it may be less effective in tumors with different surface profiles. ICG-Glow’s tannic acid approach offers a different interaction landscape, potentially broadening the range of cancers that could benefit, though that hypothesis still needs to be tested across diverse tumor types.
Neither NanoICG nor ICG-Glow has been evaluated in human patients, and the current evidence comes from small-animal models. Translating these gains into the operating room will require not only safety and toxicity studies but also careful comparisons of how each formulation performs under clinical imaging systems, which differ in sensitivity and illumination from research setups.
Activatable Probes Add a New Dimension
A separate line of research pushes the concept further by making the glow itself conditional. An activatable nanoliposome encapsulates ICG in a lipid bilayer that quenches the dye’s fluorescence while it circulates in the bloodstream, then restores the signal only after the particle is taken up by tumor cells and its shell is disrupted. This “off-to-on” switch means background noise drops dramatically, because only cells that actively internalize the probe light up. In preclinical tests, the system produced sharper contrast between tumor and surrounding tissue than free dye or always-on nanoparticles.
The same study reports a photothermal effect superior to free ICG, suggesting these particles could double as therapeutic agents that heat and destroy tumor tissue under laser exposure. That dual capability (imaging plus therapy in a single particle) represents the most ambitious goal in this field. Yet it also raises the bar for safety testing. Any probe intended to generate heat inside the body must demonstrate tight control over where and when that heating occurs, as well as rapid clearance of breakdown products to avoid long-term accumulation.
Safety, Databases, and Design Choices
For clinical applications, nanoparticle biocompatibility is essential, and coatings play a direct role in how particles interact with blood components, immune cells, and organs of clearance. Researchers routinely turn to large biomedical databases such as NCBI resources to cross-check toxicity reports, track related formulations, and compare pharmacokinetic profiles across studies. These repositories help teams avoid repeating designs that have already shown unfavorable safety signals and instead refine architectures that balance performance with tolerability.
Tools like personalized NCBI dashboards also allow investigators to organize literature on specific nanoparticle chemistries, receptors, and imaging endpoints. By aggregating data on particle size, surface charge, and coating materials, scientists can identify patterns, for example, which size ranges tend to accumulate in the liver versus tumors, or how different polyphenol shells influence immune recognition. That evidence base informs the next generation of ICG carriers, including whether to prioritize passive accumulation, active targeting ligands, or activatable mechanisms.
From Bench to Operating Room
Taken together, ICG-Glow, NanoICG, and activatable nanoliposomes illustrate a spectrum of design strategies aimed at the same clinical need: giving surgeons a more reliable way to see cancer in real time. The polymer–tannic acid shell of ICG-Glow emphasizes stability and broad tumor affinity; the hyaluronic-acid matrix of NanoICG focuses on receptor-mediated uptake; and the activatable liposome architecture trades constant brightness for a dramatic boost in contrast once inside tumor cells.
The next steps will likely involve side-by-side comparisons of these systems in standardized animal models, followed by early-phase clinical trials that monitor imaging performance, safety, clearance, and ease of integration into existing surgical workflows. Regulatory agencies will scrutinize how long nanoparticles persist in the body, whether they trigger immune reactions, and how consistently they highlight malignant tissue across patient populations.
If even one of these formulations translates successfully, the impact on oncologic surgery could be significant. More accurate margin detection could reduce repeat operations, spare healthy tissue, and provide surgeons with immediate feedback on whether they have removed all visible disease. For now, ICG-Glow and its peers remain in the realm of preclinical promise, but the convergence of smarter coatings, activatable designs, and robust data resources is steadily pushing fluorescent-guided cancer surgery toward sharper, more dependable vision in the operating room.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
